Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Return on Capital Employed (2017 - 2025)

Historic Return on Capital Employed for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to 0.33%.

  • Adma Biologics' Return on Capital Employed fell 100.0% to 0.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.33%, marking a year-over-year decrease of 100.0%. This contributed to the annual value of 0.39% for FY2024, which is 3200.0% up from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Return on Capital Employed is 0.33%, which was down 100.0% from 0.34% recorded in Q2 2025.
  • Adma Biologics' Return on Capital Employed's 5-year high stood at 0.36% during Q4 2024, with a 5-year trough of 0.32% in Q1 2021.
  • Over the past 5 years, Adma Biologics' median Return on Capital Employed value was 0.06% (recorded in 2023), while the average stood at 0.01%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first skyrocketed by 3300bps in 2024, then plummeted by -100bps in 2025.
  • Adma Biologics' Return on Capital Employed (Quarter) stood at 0.26% in 2021, then surged by 46bps to 0.14% in 2022, then surged by 154bps to 0.07% in 2023, then soared by 384bps to 0.36% in 2024, then decreased by -9bps to 0.33% in 2025.
  • Its Return on Capital Employed was 0.33% in Q3 2025, compared to 0.34% in Q2 2025 and 0.34% in Q1 2025.